Recombinant SP-D Reduces Emphysema in Mice
Author Information
Author(s): Knudsen Lars, Ochs Matthias, MacKay Rosemarie, Townsend Paul, Deb Roona, Mühlfeld Christian, Richter Joachim, Gilbert Fabian, Hawgood Samuel, Reid Kenneth, Clark Howard
Primary Institution: University of Göttingen
Hypothesis
Does treatment with rfhSP-D reduce structural abnormalities in SP-D deficient mice?
Conclusion
Treatment with rfhSP-D leads to reduced emphysema and corrected type II cell changes in SP-D deficient mice.
Supporting Evidence
- After 3 weeks of treatment, alveolar number was higher and mean alveolar size was smaller compared to saline-treated controls.
- Type II cell number and size were smaller as a consequence of treatment.
- The total volume of lamellar bodies per type II cell and per lung was smaller after 6 weeks of treatment.
Takeaway
Researchers gave a special protein to mice that usually have lung problems, and it helped their lungs get better.
Methodology
SP-D knock-out mice were treated with rfhSP-D and compared to control groups using stereological analysis.
Potential Biases
Potential bias in treatment administration and analysis methods.
Limitations
The study was limited to a specific mouse model and may not fully translate to human conditions.
Participant Demographics
SP-D knock-out mice aged 3 to 12 weeks.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website